Moderate to severe diabetic retinopathy (DR) patients are a step closer to gaining an FDA indication for anti-VEGF Eylea (aflibercept, Regeneron) therapy as the drug’s manufacturer announces its Phase III trial results. The study shows that 80% of patients who were given an injection every eight weeks showed an improvement of two steps or more from baseline in diabetic retinopathy severity score (DRSS). Only 15% of a control group improved that much. Another group was given the injection once every 16 weeks and 65% of them showed similar improvement.
The company adds that the injections also lowered vision-threatening complications by 82% to 85% and the development of center-involved diabetic macular edema by 68% to 74% compared with sham injection.
Eylea is already approved for a number of patients, including age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and DR in patients with diabetic macular edema.
|Kwok D. Eylea (aflibercept) injection improves diabetic retinopathy and reduces vision-threatening complications in phase 3 trial. Regeneron. investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-improves-diabetic-retinopathy-and. Published October 25, 2018. Accessed October 26, 2018.|